Mostrar el registro sencillo del ítem

dc.contributor.author
Bravo, Alicia Inés  
dc.contributor.author
Aris, Mariana  
dc.contributor.author
Marylou Panouillot  
dc.contributor.author
Porto, Martina  
dc.contributor.author
Dieu Nosjean, Marie Caroline  
dc.contributor.author
Teillaud, Jean Luc  
dc.contributor.author
Barrio, Maria Marcela  
dc.contributor.author
Mordoh, José  
dc.date.available
2023-12-20T14:04:10Z  
dc.date.issued
2023-08  
dc.identifier.citation
Bravo, Alicia Inés; Aris, Mariana; Marylou Panouillot; Porto, Martina; Dieu Nosjean, Marie Caroline; et al.; HEV-associated dendritic cells are observed in metastatic tumor-draining lymph nodes of cutaneous melanoma patients with longer distant metastasis-free survival after adjuvant immunotherapy; Frontiers Media; Frontiers in immunology; 14; 8-2023; 1-15  
dc.identifier.issn
1664-3224  
dc.identifier.uri
http://hdl.handle.net/11336/220894  
dc.description.abstract
Introduction: Tissue biomarkers that aid in identifying cutaneous melanoma (CM) patients who will benefit from adjuvant immunotherapy are of crucial interest. Metastatic tumor-draining lymph nodes (mTDLN) are the first encounter site between the metastatic CM cells and an organized immune structure. Therefore, their study may reveal mechanisms that could influence patients´ outcomes. Methods: Twenty-nine stage-III CM patients enrolled in clinical trials to study the vaccine VACCIMEL were included in this retrospective study. After radical mTDLN dissection, patients were treated with VACCIMEL (n=22) or IFNα-2b (n=6), unless rapid progression (n=1). Distant Metastasis-Free Survival (DMFS) was selected as an end-point. Two cohorts of patients were selected: one with a good outcome (GO) (n=17; median DMFS 130.0 months), and another with a bad outcome (BO) (n=12; median DMFS 8.5 months). We analyzed by immunohistochemistry and immunofluorescence the expression of relevant biomarkers to tumor-cell biology and immune cells and structures in mTDLN, both in the tumor and peritumoral areas. Results: In BO patients, highly replicating Ki-67+ tumor cells, low tumor HLA-I expression and abundant FoxP3+ lymphocytes were found (p=0.037; p=0.056 and p=0.021). In GO patients, the most favorable biomarkers for prolonged DMFS were the abundance of peri- and intra-tumoral CD11c+ cells (p=0.0002 and p=0.001), peri-tumoral DC-LAMP+ dendritic cells (DCs) (p=0.001), and PNAd+ High Endothelial Venules (HEVs) (p=0.004). Most strikingly, we describe in GO patients a peculiar, heterogeneous structure that we named FAPS (Favoring Antigen-Presenting Structure), a triad composed of DC, HEV and CD62L+ naïve lymphocytes, whose postulated role would be to favor tumor antigen (Ag) priming of incoming naïve lymphocytes. We also found in GO patients a preferential tumor infiltration of CD8+ and CD20+ lymphocytes (p=0.004 and p=0.027), as well as peritumoral CD20+ aggregates, with no CD21+ follicular dendritic cells detected (p=0.023). Heterogeneous infiltration with CD64+CD68-CD163-, CD64+CD68+CD163- and CD64+CD68+CD163+ macrophages were observed in both cohorts. Discussion: The analysis of mTDLN in GO and BO patients revealed marked differences. This work highlights the importance of analyzing resected mTDLN from CM patients and suggests a correlation between tumor and immune characteristics that may be associated with a spontaneous or vaccine-induced long DMFS. These results should be confirmed in prospective studies.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Frontiers Media  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
CUTANEOUS MELANOMA  
dc.subject
DENDRITIC CELLS  
dc.subject
DISTANT METASTASIS-FREE SURVIVAL  
dc.subject
HIGH ENDOTHELIAL VENULES  
dc.subject
METASTATIC TUMOR-DRAINING LYMPH NODES  
dc.subject.classification
Oncología  
dc.subject.classification
Medicina Clínica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
HEV-associated dendritic cells are observed in metastatic tumor-draining lymph nodes of cutaneous melanoma patients with longer distant metastasis-free survival after adjuvant immunotherapy  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2023-12-19T23:20:48Z  
dc.journal.volume
14  
dc.journal.pagination
1-15  
dc.journal.pais
Suiza  
dc.journal.ciudad
Lausanne  
dc.description.fil
Fil: Bravo, Alicia Inés. Fundación Instituto Leloir; Argentina  
dc.description.fil
Fil: Aris, Mariana. Fundación Cáncer. Centro de Investigaciones Oncológicas; Argentina  
dc.description.fil
Fil: Marylou Panouillot. Sorbonne University; Francia  
dc.description.fil
Fil: Porto, Martina. Fundación Cáncer. Centro de Investigaciones Oncológicas; Argentina  
dc.description.fil
Fil: Dieu Nosjean, Marie Caroline. Sorbonne University; Francia  
dc.description.fil
Fil: Teillaud, Jean Luc. Sorbonne University; Francia  
dc.description.fil
Fil: Barrio, Maria Marcela. Fundación Cáncer. Centro de Investigaciones Oncológicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina  
dc.description.fil
Fil: Mordoh, José. Fundación Cáncer. Centro de Investigaciones Oncológicas; Argentina. Fundación Instituto Leloir; Argentina  
dc.journal.title
Frontiers in immunology  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fimmu.2023.1231734/full  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.3389/fimmu.2023.1231734